Myocarditis: A Medical-Legal Guide for Attorneys

Introduction

Myocarditis — inflammation of the heart muscle — occupies a distinctive place in medical malpractice litigation because it is simultaneously uncommon, clinically deceptive, and capable of killing a previously healthy child or young adult within hours. It frequently mimics far more benign conditions (viral illness, gastroenteritis, asthma, anxiety, or musculoskeletal chest pain), and it strikes precisely the demographic — young, otherwise healthy patients — in which serious cardiac disease is least expected. When the diagnosis is missed and the outcome is catastrophic, the gap between an "obvious viral illness" and a fatal cardiac emergency becomes the heart of the dispute.

At the same time, the medicine has changed dramatically. Over the past two decades, high-sensitivity troponin assays, cardiac magnetic resonance imaging (CMR), risk-stratified management pathways, and mechanical circulatory support have transformed both diagnosis and survival. Understanding what the standard of care actually required at the relevant time — and what modern evidence does and does not establish about preventability — is essential to any fair evaluation of a myocarditis case.

This article is written to help attorneys, insurers, and healthcare organizations understand the medicine, identify the recurring targets of litigation, appreciate the legitimate defenses, and recognize where genuine scientific uncertainty limits confident conclusions. It is not legal advice and does not advocate for either plaintiffs or defendants.

Clinical Vignette

The following scenario is a hypothetical composite created for educational purposes and does not depict any actual patient or case.

A previously healthy 19-year-old college student presents to an urgent care clinic with three days of fatigue, low-grade fever, and intermittent chest discomfort that he attributes to a recent "chest cold." He reports that the discomfort worsens when lying flat. Vital signs show a mildly elevated heart rate; the remainder of the examination is documented as unremarkable. He is diagnosed with a viral upper respiratory infection, advised to rest and hydrate, and discharged without an electrocardiogram (ECG) or laboratory testing.

Two days later he collapses at home. Emergency medical services find him in cardiac arrest. Despite resuscitation and transfer to a tertiary center, he dies. Autopsy demonstrates lymphocytic myocarditis.

This scenario illustrates the core medical-legal tension in myocarditis: a nonspecific presentation that overlaps almost entirely with self-limited viral illness, a young patient in whom cardiac disease is not anticipated, and a rapid, unforgiving trajectory. The central questions become whether the presentation — particularly chest pain worse when supine, in the setting of a recent viral syndrome — should have triggered at least a basic cardiac evaluation, and whether earlier recognition would, more probably than not, have changed the outcome.

What Is Myocarditis?

Myocarditis is an inflammatory injury to the myocardium. It affects an estimated 4 to 14 people per 100,000 each year worldwide and disproportionately affects young adults (Ammirati and Moslehi, JAMA, 2023). The most common causes are viral infections (including influenza and coronaviruses), systemic autoimmune disorders, certain drugs — notably immune checkpoint inhibitor cancer therapies — and, rarely, vaccines.

Clinically, myocarditis classically manifests in one of three ways, and clinicians across many settings are expected to be aware of them (Drazner et al., 2024 ACC Expert Consensus Decision Pathway):

• Chest pain (the most common presentation, sometimes mimicking a heart attack)
• Heart failure or cardiogenic shock (breathlessness, fatigue, fluid overload, poor perfusion)
• Arrhythmia-related symptoms (palpitations, fainting, or sudden cardiac death)

A recent viral illness followed by any of these cardiovascular symptoms in a young person is a recognized red flag.

The 2024 ACC consensus document introduced a four-stage framework that is increasingly reflected in expert testimony:

• Stage A — at risk (exposure to a known trigger) but no evidence of injury
• Stage B — inflammation or injury present but asymptomatic
• Stage C — symptomatic myocarditis
• Stage D — advanced myocarditis with hemodynamic (shock) or electrical (dangerous rhythm) instability

Fulminant myocarditis is the severe, rapidly progressive form that presents with shock or life-threatening arrhythmias and drives most of the mortality — and most of the litigation.

Why Myocarditis Is Difficult to Diagnose

Several features make myocarditis genuinely hard to recognize, and these features are central to both liability and defense analysis:

• The presentation is nonspecific. There is no single pathognomonic sign or symptom (Zeppenfeld et al., 2022 ESC Guidelines). Symptoms overlap with viral illness, pneumonia, asthma, gastroenteritis, panic attacks, and musculoskeletal pain.
• It strikes low-suspicion patients. Myocarditis predominantly affects children and young adults, in whom clinicians are not primed to expect serious heart disease.
• Early testing can be normal or nonspecific. ECG changes are sensitive but not specific, troponin may be elevated but is not always, and a normal initial test does not exclude the disease. Notably, some patients with myocarditis do not have an elevated troponin (Drazner et al., 2024 ACC Expert Consensus Decision Pathway).
• Deterioration can be rapid. A patient who appears stable can progress to cardiogenic shock, malignant arrhythmia, or sudden death within hours.

In children, these challenges are amplified. The American Heart Association's 2021 scientific statement on pediatric myocarditis emphasizes that the diagnosis is frequently delayed or missed because children commonly present with nonspecific or extracardiac complaints — respiratory symptoms, vomiting, poor feeding, lethargy, and abdominal pain — that are readily attributed to more common childhood illnesses (Law et al., Circulation, 2021). This is why pediatric misdiagnosis, particularly as asthma, pneumonia, or gastroenteritis, is a recurring litigation theme.

Modern Advances That Have Improved Diagnosis and Reduced Mortality

A defining feature of contemporary myocarditis care — and a point the plaintiff and defense will often frame very differently — is that outcomes have improved substantially, and the diagnostic toolkit has expanded.

Noninvasive diagnosis has largely replaced biopsy for most patients

Historically, definitive diagnosis required endomyocardial biopsy (EMB). Today, high-sensitivity troponin and cardiac MRI allow noninvasive assessment of cardiac inflammation and injury (Drazner et al., 2024 ACC Expert Consensus Decision Pathway). CMR, using T1 and T2 mapping under the updated Lake Louise criteria, has become the cornerstone of noninvasive diagnosis and carries a Class 1 guideline recommendation, reserving biopsy for higher-risk or diagnostically uncertain cases (Schulz-Menger et al., 2025 ESC Guidelines; Ammirati and Moslehi, JAMA, 2023).

Risk stratification directs intensity of care

Modern practice separates uncomplicated from complicated myocarditis. Roughly 75% of hospitalized patients have an uncomplicated course with a mortality rate approaching zero, whereas myocarditis complicated by acute heart failure or ventricular arrhythmias carries an approximately 12% rate of in-hospital death or heart transplant (Ammirati and Moslehi, JAMA, 2023). This stratification lets clinicians escalate the sickest patients aggressively while safely managing the majority.

Mechanical circulatory support has transformed fulminant myocarditis

For patients in cardiogenic shock, temporary mechanical circulatory support — including venoarterial extracorporeal membrane oxygenation (VA-ECMO), intra-aortic balloon pumps, and percutaneous ventricular assist devices — can sustain a patient through the acute inflammatory phase until the heart recovers. Multicenter registries report short-term transplant-free survival of roughly 66% to 76% in fulminant myocarditis supported temporarily with such devices (Ammirati and Moslehi, JAMA, 2023). A striking illustration comes from the "Chinese protocol" (life support–based comprehensive treatment regimen) combining mechanical support, immunomodulation, and neuraminidase inhibitors, reported to reduce in-hospital mortality of fulminant myocarditis from approximately 50% to under 5% in that experience (Jiang et al., Scientific Reports, 2023). These figures come from specialized centers and observational data, but they underscore how dramatically supportive technology has changed the trajectory of the sickest patients.

Etiology-directed immunosuppression helps specific subtypes

For giant cell myocarditis, eosinophilic myocarditis, cardiac sarcoidosis, and autoimmune-associated or immune checkpoint inhibitor–related myocarditis, corticosteroids and other immunosuppressive agents are appropriate and, for giant cell myocarditis in particular, combination immunosuppression has substantially improved a once nearly uniformly fatal prognosis (Vosko and Wallner, Heart Failure Reviews, 2026; McDonagh et al., 2021 ESC Heart Failure Guidelines).

A crucial counterpoint for causation analysis: these advances primarily help patients who reach appropriate care. Registry data show that background hospital mortality for myocarditis has remained relatively stable (around 2–2.5%) over many years, because most cases were never the high-risk cases (Rottmann et al., Clinical Research in Cardiology, 2025). The advances matter most for the fulminant subset — which is exactly the subset most likely to be litigated. This distinction is central: the argument that "modern treatment saves lives" is strongest, and most contestable, precisely in the cases where a delay is alleged to have foreclosed access to that treatment.

Current Evidence-Based Standards of Care

Attorneys should understand that myocarditis care rests on a mix of firm recommendations and areas of acknowledged uncertainty. Distinguishing the two is essential.

Recognition and initial evaluation (well supported)

When the clinical picture is consistent with myocarditis, guidelines call for an initial screening set: ECG, complete blood count, cardiac biomarkers (high-sensitivity troponin, and in some cases C-reactive protein and a natriuretic peptide), and echocardiography, with exclusion of coronary artery disease when clinically appropriate (Drazner et al., 2024 ACC Expert Consensus Decision Pathway). This initial screening step is the most concrete standard-of-care anchor and the one most often at issue in missed-diagnosis claims.

Triage and referral (well supported)

Patients with reduced ventricular function, hemodynamic instability, or electrical instability (dangerous rhythms or high-grade heart block) should be recognized as high-risk and referred to centers capable of biopsy, mechanical support, and management of complex arrhythmias (Zeppenfeld et al., 2022 ESC Guidelines; Drazner et al., 2024 ACC Expert Consensus Decision Pathway).

Definitive diagnosis (well supported)

CMR is the preferred noninvasive confirmatory test for stable patients; endomyocardial biopsy is reserved for patients with shock, refractory heart failure, ventricular arrhythmias, high-grade AV block, or suspected giant cell/eosinophilic disease where a histologic diagnosis will change treatment (Basso, NEJM, 2022).

Supportive and heart failure therapy (well supported)

When left ventricular dysfunction is present, guideline-directed heart failure therapy should be started and continued, generally for at least six months after recovery. Intense physical and athletic activity should be avoided during the acute phase and for a period after recovery (McDonagh et al., 2021 ESC Heart Failure Guidelines).

Immunosuppression (context-dependent, partly uncertain)

Immunosuppression is indicated for specific autoimmune or histologic subtypes (giant cell, eosinophilic, sarcoid, autoimmune-associated) but is not recommended routinely for uncomplicated viral or virus-negative myocarditis absent such evidence (McDonagh et al., 2021 ESC Heart Failure Guidelines). The broad use of corticosteroids in typical acute myocarditis remains controversial and is not supported by high-quality randomized evidence (Ammirati and Moslehi, JAMA, 2023).

Advanced therapy (well supported for the sickest)

Stage D patients require inotropic support, temporary mechanical circulatory support, and consideration of durable ventricular assist devices or transplant at advanced heart failure centers (Drazner et al., 2024 ACC Expert Consensus Decision Pathway).

A recurring theme for attorneys: the recognition and workup steps are where the standard of care is most concrete and most defensible to litigate. The treatment steps — particularly immunosuppression in ordinary viral myocarditis — involve genuine clinical judgment and unsettled evidence, which makes rigid standard-of-care assertions in that domain more vulnerable.

Common Allegations in Medical Malpractice Litigation

Myocarditis claims tend to cluster around a familiar set of alleged failures:

• Failure to consider the diagnosis in a young patient with chest pain, unexplained tachycardia, or a recent viral illness followed by cardiac symptoms.
• Failure to obtain a basic ECG in a patient presenting with chest pain or concerning cardiopulmonary symptoms.
• Failure to obtain cardiac biomarkers (troponin) when the presentation warranted it.
• Misattribution to a benign condition — viral syndrome, gastroenteritis, asthma, pneumonia, anxiety, or musculoskeletal pain — particularly in children.
• Failure to recognize red flags such as chest pain worse when lying flat, resting tachycardia out of proportion to fever, syncope, or signs of poor perfusion.
• Failure to recognize and act on abnormal vital signs, including persistent tachycardia or hypotension.
• Premature discharge despite concerning findings, or without adequate return precautions.
• Failure to escalate or transfer a deteriorating or high-risk patient to a center capable of advanced support.
• Delayed recognition of fulminant disease and delayed initiation of mechanical circulatory support.
• Documentation deficiencies that obscure what was assessed, considered, and communicated.

Medical Causation

Causation is often the decisive — and most contested — issue in myocarditis litigation, frequently more so than breach of the standard of care. The central question is whether earlier recognition and treatment would, more probably than not, have changed the outcome.

Several features make causation analysis distinctive in myocarditis:

Rapid, sometimes unpredictable progression

Some patients deteriorate so quickly that even prompt, correct diagnosis might not have altered the outcome. Sudden cardiac death can be the first manifestation; in young adults, myocarditis accounts for an estimated 2–12% of sudden cardiac deaths, and death can precede any opportunity for intervention (Zeppenfeld et al., 2022 ESC Guidelines).

The natural history is heterogeneous

Most myocarditis is self-limited, but a subset progresses to fulminant disease, chronic dilated cardiomyopathy (reported in up to roughly 20% of cases), or death. Distinguishing an unavoidable outcome of aggressive disease from a preventable consequence of delay is the crux of expert disagreement.

The "earlier treatment" argument cuts both ways

Plaintiffs argue that timely diagnosis would have permitted heart failure therapy, monitoring, and — critically — access to mechanical circulatory support that now yields transplant-free survival of roughly two-thirds to three-quarters of fulminant cases. The defense counters that supportive care does not reverse the underlying inflammatory injury, that no proven therapy reliably halts myocardial damage in ordinary viral myocarditis, and that the deterioration may have been too rapid or too severe to interrupt.

Probability versus possibility

Because myocarditis outcomes span the full range from complete recovery to sudden death, causation opinions must grapple honestly with baseline probabilities rather than assuming that any delay caused the harm.

Typical alleged injuries include sudden cardiac death, progression to end-stage heart failure requiring transplant, anoxic neurologic injury following cardiac arrest, and chronic dilated cardiomyopathy with lifelong disability.

Common Misconceptions

• "A normal ECG rules out myocarditis." False. ECG abnormalities are sensitive but nonspecific, and findings can be subtle; a normal or nonspecific ECG does not exclude the disease (McDonagh et al., 2021 ESC Heart Failure Guidelines).
• "A normal troponin excludes myocarditis." False. Some patients with myocarditis do not have elevated troponin, and whether a normal high-sensitivity troponin can reliably rule out the disease remains under study (Drazner et al., 2024 ACC Expert Consensus Decision Pathway).
• "A young, healthy, well-appearing patient cannot have life-threatening heart disease." False. Myocarditis characteristically affects young, previously healthy people and can progress rapidly from a well appearance to shock or sudden death.
• "Chest pain in a young person is almost always benign." Misleading. While most is benign, chest pain — especially pleuritic or positional chest pain after a viral illness — is the single most common presentation of myocarditis.
• "Because most myocarditis resolves on its own, missing it rarely matters." False. The self-limited majority coexists with a fulminant minority for whom recognition and access to advanced support are life-determining.
• "Vaccine-associated myocarditis is as dangerous as viral myocarditis." Not supported by the data. Myocarditis after mRNA COVID-19 vaccination has generally been mild with a substantially more favorable prognosis than viral infection–related myocarditis (Lai et al., Journal of the American College of Cardiology, 2022).

Long-Term Outcomes and Damages

Damages in myocarditis cases are driven by the severity of the surviving injury or the fact of death:

• Death, including sudden cardiac death in a previously healthy child or young adult, supporting wrongful death claims.
• Anoxic brain injury following cardiac arrest and resuscitation, with resulting neurologic and cognitive impairment.
• Chronic heart failure and dilated cardiomyopathy, which may develop in a meaningful minority of survivors and can require lifelong medication, device therapy, or transplant.
• Need for heart transplantation or durable mechanical support, with attendant lifelong immunosuppression, complications, and the possibility — for giant cell and sarcoid disease — of recurrence in the transplanted heart.
• Arrhythmias and sudden death risk, sometimes warranting an implantable defibrillator.
• Activity restriction and diminished quality of life, including restrictions on athletics and employment.

Because myocarditis often strikes young patients, damages calculations frequently involve long life expectancies, extensive future care, and substantial lost earning capacity.

Medical Records That Matter

Meaningful evaluation of a myocarditis case depends on the complete longitudinal record, not isolated encounters. Records that frequently prove decisive include:

• Triage and nursing notes, including the initial complaint and vital signs
• Serial vital-sign trends, especially heart rate, blood pressure, and oxygen saturation over time
• Documentation of the history, particularly any antecedent viral illness and the character of chest pain
• ECG tracings and their interpretation and timing
• Cardiac biomarker results (troponin) and the timing of testing
• Echocardiography and CMR reports
• Endomyocardial biopsy and pathology reports, where obtained
• Reassessment documentation before any discharge decision
• Discharge instructions and return precautions
• Timing of medications, transfer, and escalation of care
• Emergency medical services and resuscitation records
• Autopsy findings in fatal cases
• Intensive care and mechanical circulatory support documentation

Timing is often everything in these cases; records establishing the exact sequence of vital signs, testing, interpretation, and intervention are the backbone of both liability and causation analysis.

The Role of Cardiac and Pediatric Expertise

Myocarditis sits at the intersection of general medicine, emergency medicine, cardiology, and — when the patient is a child — pediatrics and pediatric cardiology. Several points make specialized expertise particularly important:

The standard of care is setting- and era-specific

What a reasonable urgent care clinician, emergency physician, or cardiologist should have done depends on the presentation, the resources available, and the state of the evidence at the relevant time. The diagnostic paradigm has shifted substantially (for example, the move from routine biopsy to CMR), so expert review must be anchored to contemporaneous standards.

Pediatric physiology and presentation differ from adults

Children more often present with nonspecific or extracardiac complaints and can compensate until late, then decompensate abruptly; pediatric-specific guidance recognizes these distinct challenges (Law et al., Circulation, 2021). Applying adult expectations to a pediatric case, or vice versa, is a common analytical error.

Causation requires disease-specific judgment

Assessing whether earlier intervention would have altered the outcome demands familiarity with the natural history of the specific myocarditis subtype and with the real-world results of advanced therapies.

Balanced interpretation matters

A qualified expert can distinguish a genuine deviation from the standard of care from an adverse outcome of aggressive disease — and can recognize when the evidence simply does not permit a confident conclusion in either direction.

Key Takeaways for Attorneys

• Myocarditis is rare but high-stakes, striking young, previously healthy patients and capable of causing sudden death or lifelong disability.
• The three classic presentations are chest pain, heart failure/shock, and arrhythmia symptoms, and a recent viral illness followed by cardiac symptoms is a recognized red flag.
• The most concrete standard-of-care question is usually the initial workup — whether an ECG and cardiac biomarkers were obtained when the presentation warranted them — rather than the choice of downstream therapy.
• Normal early tests do not exclude myocarditis. Troponin can be normal, and ECG changes are nonspecific.
• Diagnosis has shifted from biopsy to noninvasive testing. Cardiac MRI is now the cornerstone confirmatory test for stable patients, with biopsy reserved for high-risk or uncertain cases.
• Modern management has meaningfully improved survival in the fulminant subset, chiefly through risk stratification and mechanical circulatory support, which yields transplant-free survival in roughly two-thirds to three-quarters of supported fulminant cases.
• Causation is frequently the decisive and most contested issue. The heterogeneity of the natural history — from spontaneous recovery to sudden death — makes the "would earlier care have changed the outcome" question genuinely difficult.
• Treatment standards are not uniform. Immunosuppression is appropriate for specific subtypes but controversial and unproven for ordinary viral myocarditis; rigid claims in this domain are vulnerable.
• Pediatric cases require pediatric expertise, because children present atypically and can deteriorate rapidly.
• Timing-focused records are the backbone of these cases — serial vital signs, the sequence and interpretation of testing, reassessment, and escalation — and must be reviewed against the standards in force at the time of care.

References

• Ammirati E, Moslehi JJ. JAMA. 2023.
• Drazner MH, et al. 2024 ACC Expert Consensus Decision Pathway.
• Zeppenfeld K, et al. 2022 ESC Guidelines.
• Law YM, et al. Circulation. 2021.
• Schulz-Menger J, et al. 2025 ESC Guidelines.
• Jiang L, et al. Scientific Reports. 2023.
• Vosko I, Wallner M. Heart Failure Reviews. 2026.
• McDonagh TA, et al. 2021 ESC Heart Failure Guidelines.
• Rottmann H, et al. Clinical Research in Cardiology. 2025.
• Basso C. New England Journal of Medicine. 2022.
• Lai FTT, et al. Journal of the American College of Cardiology. 2022.